Category Archives: news

NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma

See the press release on Business Wire

NiKang Therapeutics® Presents Discovery of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 PROTAC Degrader for Cancer Therapy, at the EORTC-NCI-AACR Symposium 2024

See the press release on Business Wire

NiKang Therapeutics® to Present Preliminary Results of Phase 1/2 Clinical Trial of NKT2152 in Patients with Previously Treated Advanced Clear Cell Renal Cell Carcinoma at ESMO 2024 Congress

See the press release on Business Wire

NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression

See the press release on Business Wire

NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024

See the press release on Business Wire

NiKang Therapeutics Appoints Joanne Lager,M.D., as Chief Medical Officer

See the press release on Business Wire

NiKang Therapeutics Enters Into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma

See the press release on Business Wire

NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors

See the press release on Business Wire

NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China

See the press release on Business Wire

NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152’s Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022

See the press release on Business Wire